Search Results - "Aujay, Monette A."

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo by Saunders, Laura R, Bankovich, Alexander J, Anderson, Wade C, Aujay, Monette A, Bheddah, Sheila, Black, KristenAnn, Desai, Radhika, Escarpe, Paul A, Hampl, Johannes, Laysang, Amy, Liu, David, Lopez-Molina, Javier, Milton, Milly, Park, Albert, Pysz, Marybeth A, Shao, Hui, Slingerland, Brian, Torgov, Michael, Williams, Samuel A, Foord, Orit, Howard, Philip, Jassem, Jacek, Badzio, Andrzej, Czapiewski, Piotr, Harpole, David H, Dowlati, Afshin, Massion, Pierre P, Travis, William D, Pietanza, M Catherine, Poirier, J T, Rudin, Charles M, Stull, Robert A, Dylla, Scott J

“…The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), remain among the most deadly…”
Get more information

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis by Basler, Michael, Aujay, Monette A, Groettrup, Marcus, Kalim, Khalid W, Shields, Jamie, Jiang, Jing, Kirk, Christopher J, Muchamuel, Tony, Suzuki, Erika, Bennett, Mark K, Ring, Eileen R, Demo, Susan D, Shwonek, Peter, Lauer, Christoph, Sylvain, Catherine, Parlati, Francesco

“…Christopher Kirk and his colleagues have developed the first specific inhibitor of the immunoproteasome. They find that the immunoproteasome has a major role…”
Get full text

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome by DEMO, Susan D, KIRK, Christopher J, SHENK, Kevin D, SMYTH, Mark S, SUN, Congcong M, VALLONE, Marcy K, WOO, Tina M, MOLINEAUX, Christopher J, BENNETT, Mark K, AUJAY, Monette A, BUCHHOLZ, Tonia J, DAJEE, Maya, HO, Mark N, JING JIANG, LAIDIG, Guy J, LEWIS, Evan R, PARLATI, Francesco

“…Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma…”
Get full text

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047) by Zhou, Han-Jie, Aujay, Monette A, Bennett, Mark K, Dajee, Maya, Demo, Susan D, Fang, Ying, Ho, Mark N, Jiang, Jing, Kirk, Christopher J, Laidig, Guy J, Lewis, Evan R, Lu, Yan, Muchamuel, Tony, Parlati, Francesco, Ring, Eileen, Shenk, Kevin D, Shields, Jamie, Shwonek, Peter J, Stanton, Timothy, Sun, Congcong M, Sylvain, Catherine, Woo, Tina M, Yang, Jinfu

“…Proteasome inhibition has been validated as a therapeutic modality in the treatment of multiple myeloma and Non-Hodgkin’s lymphoma. Carfilzomib, an epoxyketone…”
Get full text

PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo by Singh, Ajita V., Bandi, Madhavi, Aujay, Monette A., Kirk, Christopher J., Hark, David E., Raje, Noopur, Chauhan, Dharminder, Anderson, Kenneth C.

“…Summary PR‐924 is an LMP‐7‐selective tripeptide epoxyketone proteasome inhibitor that covalently modifies proteasomal N‐terminal threonine active sites. In the…”
Get full text

Evaluation of PNU-159682 antibody drug conjugates (ADCs) by Holte, Dane, Lyssikatos, Joseph P., Valdiosera, Amanda M., Swinney, Zachary, Sisodiya, Vikram, Sandoval, Joseph, Lee, Christina, Aujay, Monette A., Tchelepi, Robert B., Hamdy, Omar M., Gu, Christine, Lin, Baiwei, Sarvaiya, Hetal, Pysz, Marybeth A., Laysang, Amy, Williams, Samuel, Jun Lee, Dong, Holda, Magda K., Purcell, James W., Gavrilyuk, Julia

“…[Display omitted] PNU-159682 is a highly potent secondary metabolite of nemorubicin belonging to the anthracycline class of natural products. Due to its…”
Get full text

Elvn-001, a Next Generation ATP-Competitive ABL1 Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia by Gross, Stefan D, Eide, Christopher A., Burkard, Michael R, Reister Schultz, Anna, Aujay, Monette A, Kintz, Samuel, Druker, Brian J., Lyssikatos, Joseph P

Get full text

Abstract NT-113: SC-003, AN ANTIBODY-DRUG CONJUGATE TARGETING DIPEPTIDASE 3, EXHIBITS POTENT ANTI-TUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF HIGH GRADE SEROUS OVARIAN CANCER by Wiedemeyer, Wolf R., Bheddah, Sheila, Saechao, Christine, French, Dorothy, Huntzicker, Erik, Kempema, Aaron, Gavrilyuk, Julia, Liu, David, Sisodiya, Vikram, He, Alina, Zhang, Zhaomei, Aujay, Monette A., Hayashi, Kristyn, Vivona, Sandro, Zhao, Xi, Walter, Kimberly, Saunders, Laura R., Hampl, Johannes, Madhavan, Shravanthi, Pysz, Marybeth, Bankovich, Alexander J., Karsunky, Holger, Dylla, Scott J.

“…Disclosures: All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie…”
Get full text

Erratum: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis by Muchamuel, Tony, Basler, Michael, Aujay, Monette A, Suzuki, Erika, Kalim, Khalid W, Lauer, Christoph, Sylvain, Catherine, Ring, Eileen R, Shields, Jamie, Jiang, Jing, Shwonek, Peter, Parlati, Francesco, Demo, Susan D, Bennett, Mark K, Kirk, Christopher J, Groettrup, Marcus

“…Nat. Med. 15, 781–787 (2009); published online 14 June 2009; corrected after print 5 November 2009 In the version of this article initially published, the…”
Get full text

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders by Parlati, Francesco, Aujay, Monette A., Demo, Susan D., Goldstein, Eileen D., Jiang, Jing, Kirk, Christopher J., Laidig, Guy J., Lu, Yan, Muchamuel, Tony, Shenk, Kevin D., Sylvain, Catherine, Sun, Congcong M., Woo, Tina M., Zhou, Han-Jie, Bennett, Mark K.

“…The clinical development of the dipeptide boronate bortezomib (Velcade™) has validated proteasome inhibition as a treatment for multiple myeloma and…”
Get full text

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome by Kirk, Christopher J., Aujay, Monette A., Ho, Mark, Jiang, Jing, Laidig, Guy J., Lewis, Evan R., Lu, Yan, Muchamuel, Tony, Woo, Tina M., Sun, Congcong M., Sylvain, Catherine, Yang, Jinfu, Zhou, Han-jie, Bennett, Mark K.

“…Clinical application of proteasome inhibitors in the treatment of hematologic malignancies such as myeloma and lymphoma is restricted in part by the necessity…”
Get full text

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity by Demo, Susan D., Aujay, Monette A., Goldstein, Eileen, Laidig, Guy J., Parlati, Francesco, Lu, Yan, Shenk, Kevin D., Sun, Congcong M., Sylvain, Catherine, Woo, Tina M., Zhou, Hanjie, Bennett, Mark K.

“…The proteasome is a multi-subunit structure responsible for degrading the majority of proteins in the cell. The three catalytic subunits in the 20S core of the…”
Get full text

A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites by Bennett, Mark K., Aujay, Monette A., Buchholz, Tonia J., Demo, Susan D., Laidig, Guy J., Sun, Congcong M., Vallone, Marcy K., Woo, Tina, Smyth, Mark S.

“…The ubiquitin-proteasome pathway constitutes a major intracellular system for protein degradation. Substrates for this pathway include misfolded or unassembled…”
Get full text